Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

RSS icon

Performing TAVR and TMVR during the same hospitalization may provide value

Patients undergoing both procedures at once tended to be sicker, but their risk of poor outcomes did not significantly increase. 

Thumbnail

New risk calculator detects TEER patients who may need to be readmitted for HF

Once the tool's performance is properly validated, it could help clinicians deliver better patient care and result in significant cost savings for health systems.

Thumbnail

TMVR with transfemoral access a 'promising option,’ early data suggest

Researchers reported at TCT 2021 that survival was 100% after 30 days.

Two-year outcomes highlight the value of TMVR for patients with severe MR

Patients continue to see the benefits of transcatheter mitral valve replacement a full two years after treatment.

Thumbnail

Mitral valve prolapse during pregnancy linked to higher risk of cardiac complications

MVP also appears to increase the risk of certain problems during childbirth. 

Thumbnail

TEER associated with ‘important and significant’ reductions in hospitalization rates

Considering the study's high-risk patient population, researchers were especially impressed by these one-year outcomes.

CUTTING-EDGE findings shine new light on mitral valve surgery after failed TEER

Overall, mitral valve surgery after TEER was associated with a 30-day mortality rate of 16.6% and one-year mortality rate of 31.3%.

Thumbnail

TEER benefits all HF patients with SMR, but men see more long-term benefits

The study's authors examined data from men and women who underwent TEER with the MitraClip device in addition to guideline-directed medical therapy. 

Displaying 81 - 88 of 116

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.